BiondVax Pharmaceuticals Ltd. BVXV Archives - Page 7 of 8

ThursdayDec 22, 2022 11:06 am

QualityStocksNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions, acted as sole bookrunner on an $8 million underwritten public offering for BiondVax Pharmaceuticals. BiondVax expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, for the advancement of its nanosized antibody (“NanoAb”) development program and general corporate purposes. To view the full…

TuesdayDec 20, 2022 2:21 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the closing of its underwritten public offering with gross proceeds to the company to be $8,000,000. The offering consists of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”) and two warrants, each to purchase one ADS. Each pre-funded unit consists of one pre-funded warrant to purchase one ADS and two warrants each to purchase one ADS. BiondVax expects to use the net proceeds, together with its existing…

FridayDec 16, 2022 12:09 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raise $8M

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance.…

TuesdayDec 13, 2022 2:52 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a…

TuesdayDec 13, 2022 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025 A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid…

MondayDec 12, 2022 12:32 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule…

FridayDec 09, 2022 10:22 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $57.00/ADS. The publication reads, “On November 30, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the third quarter of 2022 and provided a business update. The company recently announced positive preclinical results for its inhaled COVID-19 therapy. Using the industry-standard hamster model for COVID-19 therapeutics, results showed that hamsters treated with BiondVax’s NanoAb therapy had significantly (P<0.001)…

TuesdayDec 06, 2022 10:56 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”). During his career, Dobbelstein has amassed impressive experience, particularly with his research, which has focused on principles of infections and cancer. He has studied the application of anticancer drugs as antivirals and has…

WednesdayNov 30, 2022 2:07 pm

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen; the three companies are working to develop a pipeline of innovative nanosized antibody (“NanoAb”) therapies. The company is also working to regain compliance with NASDAQ listing rules regarding minimum shareholders’ equity and minimum…

TuesdayNov 29, 2022 12:00 pm

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Pipeline Focused on Creating Innovative Immunotherapeutic Products for Treating Underserved Infectious and Autoimmune Diseases

In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030 BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company…

Site Search

Company Search

Tag: BiondVax Pharmaceuticals Ltd. BVXV